Ignite Creation Date:
2024-05-06 @ 7:58 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06201000
Status:
RECRUITING
Last Update Posted:
2024-02-07
First Post:
2023-12-27
Brief Title:
Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients
Sponsor:
October 6 University
Organization:
October 6 University
Study Overview
Official Title:
Effect of Genetic Polymorphisms on the Clinical Response to Sodium-glucose Cotransporter 2 SGLT2 Inhibitors in Prevention of Cardiac Remodeling and Fibrosis in Heart Failure Patients
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Sodium-glucose cotransporter 2 SGLT2 inhibitors have shown further reductions in heart failure hospitalization cardiovascular events and mortality especially for heart failure patients
The SGLT2 gene also known as SLC5A2 solute carrier family 5 member 2 is located on chromosome 16 and is responsible for encoding SGLT2
Several SLC5A2 mutations alter SGLT2 expression membrane location or transporter function
Several common genetic variations were found in the SLC5A2 gene that may affect the response to treatment with SGLT2 inhibitors
The SGLT2 gene also known as SLC5A2 solute carrier family 5 member 2 is located on chromosome 16 and is responsible for encoding SGLT2
Several SLC5A2 mutations alter SGLT2 expression membrane location or transporter function
Several common genetic variations were found in the SLC5A2 gene that may affect the response to treatment with SGLT2 inhibitors
Detailed Description:
Sodium-glucose cotransporter-2 inhibitors SGLT-2i which were first investigated and licensed for the treatment of diabetes are now emerging as a promising class of drugs for the treatment of heart failure HF even in people without diabetes
Significant reductions in worsening heart failure or cardiovascular death were shown under treatment with dapagliflozin and empagliflozin in the trials of patients with heart failure
Several common genetic variations were found in the SLC5A2 gene that may affect the response to treatment with SGLT2 inhibitors
The most recent SLC5A2 Single Nucleotide Polymorphisms SNPs that reduce the risk of heart failure included two intronic SLC5A2 SNPs s9934336 and rs3116150 both associated with the expression levels of the transporter
This study aims to detect the association between SLC5A2 single nucleotide polymorphisms and variability in response to SGLT2 Inhibitors as well as the association between cardiac biomarkers and non-coding RNA in patients with Heart Failure
Significant reductions in worsening heart failure or cardiovascular death were shown under treatment with dapagliflozin and empagliflozin in the trials of patients with heart failure
Several common genetic variations were found in the SLC5A2 gene that may affect the response to treatment with SGLT2 inhibitors
The most recent SLC5A2 Single Nucleotide Polymorphisms SNPs that reduce the risk of heart failure included two intronic SLC5A2 SNPs s9934336 and rs3116150 both associated with the expression levels of the transporter
This study aims to detect the association between SLC5A2 single nucleotide polymorphisms and variability in response to SGLT2 Inhibitors as well as the association between cardiac biomarkers and non-coding RNA in patients with Heart Failure
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None